Results 221 to 230 of about 152,628 (302)
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott +8 more
wiley +1 more source
ABSTRACT Background Cell therapy, particularly those utilizing mesenchymal stem/stromal cells (MSCs), is gaining traction as a therapeutic option for regenerative treatment in patients with limited therapeutic options. Although the safety of MSC‐based interventions is well established, uncertainties remain regarding how genetic abnormalities and ...
Marzena Zychowicz +12 more
wiley +1 more source
Novel meriolin derivatives potently inhibit cell cycle progression and transcription in leukemia and lymphoma cells via inhibition of cyclin-dependent kinases (CDKs). [PDF]
Schmitt L +14 more
europepmc +1 more source
TrkA abundance is increased in cutaneous nerves in bortezomib‐induced neuropathy
Cutaneous nerves in bortezomib‐induced peripheral neuropathy (BIPN) show reduced nerve fiber density, increased TrkA expression, and enhanced dermal angiogenesis, highlighting a pathological switch in NGF/TrkA signaling that may contribute to nerve damage and pain. Abstract Tropomyosin receptor kinase A (TrkA), a high‐affinity receptor for nerve growth
Yuying Jin +14 more
wiley +1 more source
Compartmentalisation in cAMP signalling: A phase separation perspective
Cells rely on precise spatiotemporal control of signalling pathways to ensure functional specificity. The compartmentalisation of cyclic AMP (cAMP) and protein kinase A (PKA) signalling enables distinct cellular responses within a crowded cytoplasmic space.
Milda Folkmanaite, Manuela Zaccolo
wiley +1 more source
Background and Purpose Cyclic guanosine monophosphate (cGMP) is a ubiquitous second messenger involved in human (patho‐)physiology. Phosphodiesterase 5 (PDE5) is a major cGMP hydrolyzing enzyme in many cell types including vascular smooth muscle cells (VSMCs). Several highly selective PDE5 inhibitors are in clinical use. However, there are currently no
Kürsat Kirkgöz +8 more
wiley +1 more source

